Mattis Dementia Rating Scale
Also known as: DRS, Mattis DRS, Dementia Rating Scale
The Mattis Dementia Rating Scale (DRS) is a comprehensive 36-item clinician-administered neuropsychological battery designed to assess and quantify cognitive decline in dementia. Developed by Sandra Mattis in 1988, the DRS measures five major cognitive domains—attention, initiation/perseveration, construction, conceptualization, and memory—and provides both a total score and subscale scores. The DRS is particularly valued in neurodegenerative disease research and clinical settings for its sensitivity to cognitive change over time and its utility in detecting cognitive impairment across the dementia spectrum.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The DRS is indicated for comprehensive cognitive assessment in patients with suspected dementia, particularly when tracking change over time or differentiating between dementia types. It is more thorough than the MMSE and more balanced across cognitive domains than instruments emphasizing memory alone. The DRS is particularly useful in neurodegenerative disease research and in clinical settings where quantification of cognitive impairment is required. It is NOT diagnostic alone and should be integrated with clinical assessment, imaging, and sometimes additional testing.
Strengths & limitations
- Comprehensive yet moderately brief — assesses five major cognitive domains in 20–30 minutes, more thorough than MMSE while more efficient than full neuropsychological batteries.
- Sensitive to cognitive change — responsive to disease progression over time; used extensively in Alzheimer's and Parkinson's disease trials.
- Detailed subscales — allow identification of specific cognitive impairment patterns (e.g., predominant memory loss vs. executive dysfunction), informing differential diagnosis.
- Extensive research validation — used in thousands of studies with published normative data across diverse populations and disease groups.
- Longer than MMSE — 20–30 minutes administration limits utility in very busy primary care settings or patients with limited stamina.
- Language and education dependent — several subscales require verbal responses and intact language ability; results may be confounded in non-native speakers or those with aphasia.
- Requires training — standardized administration and scoring demand clinician expertise; not as straightforward as the MMSE.
- Copyrighted — unlike the MMSE, the DRS is proprietary (Psychological Assessment Resources) and requires licensing.
Frequently asked
What does a discrepancy between DRS Memory and Initiation/Perseveration subscales suggest?
If Memory is markedly impaired while Initiation/Perseveration is relatively preserved, the pattern suggests cortical pathology (e.g., Alzheimer's disease). Conversely, if Initiation/Perseveration is impaired with preserved Memory, the pattern suggests subcortical pathology (e.g., Parkinson's disease, vascular dementia). Always consider clinical and imaging findings alongside the DRS pattern.
How does the DRS compare to the MMSE?
The DRS is more comprehensive than the MMSE; it assesses five cognitive domains versus the MMSE's broad screening. The DRS is more sensitive to mild impairment and cognitive change over time. However, the DRS takes longer (20–30 min vs. 5–10 min), is more complex to administer, and is copyrighted (requires licensing). For screening, use MMSE; for detailed assessment or longitudinal monitoring, use DRS.
What is a clinically meaningful change on the DRS?
A DRS change of 5–10 points over 6–12 months typically reflects true cognitive decline in dementia; changes of <5 points may reflect test-retest variability or practice effects. In clinical trials, 3–4 point differences between groups are considered clinically significant. Always interpret DRS change in clinical context; isolated score change without functional decline may not indicate true progression.
Can the DRS be used in non-English speaking patients?
The DRS has been translated into several languages (e.g., Spanish, German, Chinese), but English norms are most extensive. If using a translation, verify that adequate validation and normative data exist for the language and population you're assessing. Consider hiring a bilingual neuropsychologist for valid administration.
Sources
- Mattis, S. (1988). Dementia Rating Scale (DRS). Odessa, FL: Psychological Assessment Resources. link ↗
- Monsch, A. U., Bondi, M. W., Butters, N., Salmon, D. P., Kluger, A., & Thal, L. J. (1992). Comparisons of verbal and nonverbal cognitive function in Alzheimer's disease. Neurology, 42(8), 1638-1644. link ↗
- Vangel Jr, S. J., & Lichtenberg, P. A. (2008). Mattis Dementia Rating Scale: Clinical utility in older adults. Clinical Neuropsychologist, 22(1), 71-80. link ↗
How to cite this page
ScholarGate. (2026, June 3). Mattis Dementia Rating Scale. ScholarGate. https://scholargate.app/en/neuropsychology/dementia-rating-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Addenbrooke's Cognitive ExaminationNeuropsychology↔ compare
- Alzheimer's Disease Assessment Scale-CognitiveNeuropsychology↔ compare
- Mini-Mental State ExaminationNeuropsychology↔ compare
- Saint Louis University Mental Status ExaminationNeuropsychology↔ compare
- Trail Making TestNeuropsychology↔ compare